tbuckley/cabot-search huggingface dataset:
1492MO Immune and vascular biomarkers associated with efficacy and mechanism of actions of the combination of lenvatinib (L) and eribulin (E) in leiomyosarcoma (LMS) and liposarcoma (LPS)
Authors: T.W-W. Chen, C-L. Hsu, J-C. Lee, C-C. Yen, R-L. Hong, S-C. Chen, C-W. Yu, M-L. Chen, M-C. Hsu, T-F. Kung, A-L. Cheng
Journal: Annals of Oncology (2022)
1573P Developing a patient-related predictive model for the occurrence of CINV (NOGGO-EMRISK trial): Prospective, multicentre study in Germany
Authors: J. Sehouli, G. Oskay-Öczelik, D. Zocholl, A-S. Klemt, N. Bangemann, O. Albrecht, H-J. Strittmatter, P. Wimberger, A. Kaczerowsky, R. Lorenz, W. Ruhwedel, T.N. Fehm, A. Zahn, O. Tome, M. Markert, D. Hager, A. Zorr, M. Keller, H. Rittmeister, J.P. Grabowski
Journal: Annals of Oncology (2022)
1735O PD-L1 expression on immune cells by SP142 co-localises with dendritic cells and is associated with improved overall survival (OS) with atezolizumab in patients with untreated metastatic urothelial cancer (mUC)
Authors: E. Grande Pulido, M.D. Galsky, R. Van Elzen, R. Banchereau, M. Peterson, C. Sedano, H. Koeppen, H. Li, A. Bamias, J.A. Arranz Arija, E. Kikuchi, M. De Santis, I.D. Davis, I. Mellman, S. Oh, P. Williams, S. Bernhard, C.P. Lee, M. Kockx, S. Mariathasan
Journal: Annals of Oncology (2022)
1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
Authors: L. Albiges, H.P. Gurney, V. Atduev, C. Suárez, M.A. Climent Duran, D. Pook, P. Tomczak, P. Barthelemy, J-L. Lee, T. Nalbandian, V. Stus, T. Ferguson, P. Wiechno, E. Gokmen, L. Lacombe, C. Gedye, R. Perini, M. Sharma, None C. Li, C-H. Lee
Journal: Annals of Oncology (2022)
1373P SPOP mutations (mtSPOP) are a treatment-selection biomarker in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC)
Authors: U. Swami, R.P. Graf, R. Nussenzveig, V. Fisher, H. Tukachinsky, G. Li, N. Sayegh, N. Tripathi, V. Mathew Thomas, G.R. Oxnard, E.S. Antonarakis, N. Agarwal
Journal: Annals of Oncology (2022)
1596P The G8 screening tool as an independent predictor of survival in elderly cancer patients
Authors: A. Mennitto, F. Biello, L.G. Forti, G. Siffredi, A. Mokhtar Mahmoud, F. Invernizzi, P.M. Maggiora, A. Rua, C. Branni, E. Gioffi, V. Martini, S. Gobbato, C. Pisani, E. Ferrara, M. Cappelli, E. Catania, D. Ferrante, G. Gaidano, M. Krengli, A. Gennari
Journal: Annals of Oncology (2022)
1629P Increased incidence of thymic epithelial tumors during COVID-19 pandemic: A retrospective analysis from the French RYTHMIC network
Authors: J.C. Benitez, J. Florez-Arango, M-E. Boucher, E. Dansin, M. Kerjouan, L. Bigay-Game, E. Pichon, F. Thillays, P-E. Falcoz, S. Lyubimova, Y. Oulkhouir, F. Calcagno, L. Thiberville, C. Clément-Duchêne, V. Westeel, P.A. Thomas, J-M. Maury, T. Molina, N. Girard, B. Besse
Journal: Annals of Oncology (2022)
448TiP A multicenter single arm phase II trial evaluating the safety and the efficacy of panitumumab and irinotecan for patients with NeoRAS wild-type metastatic colorectal cancer (C-PROWESS trial)
Authors: H. Osumi, N. Ishizuka, A. Takashima, Y. Kumekawa, D. Nakano, M. Shiozawa, T. Denda, R. Sawada, K. Ouchi, T. Wakatsuki, N. Boku, K. Kato, K. Yamaguchi, E. Shinozaki
Journal: Annals of Oncology (2022)
1547P Predictors of short-, medium-, and long-term survival with limited stage small cell lung cancer in the real-world
Authors: D. Dawe, R. Rittberg, O. Bucher, K. Galloway, I. Syed, D. Moldaver, K. Reynolds, J. Paul, C.H. Harlos, S. Banerji
Journal: Annals of Oncology (2022)
1377P Transcriptomic based indicators of potential therapeutic response to targeted therapy among 50,000 men with localized prostate cancer
Authors: E.M. Schaeffer, J.A. Proudfoot, E. Li, A. Weiner, J.A. Aguiar, A. Hakansson, X. Zhao, Y. Liu, E. Davicioni, A. Ross
Journal: Annals of Oncology (2022)
1712P Usefulness of schlafen-11 expression level in cstage II/III esophageal squamous cell carcinoma
Authors: T. Yamamura, K.C. Hatanaka, K. Harada, Y. Kawamoto, R. Watanabe, T. Nakamura, S. Yuki, T. Mitsuhashi, Y. Hatanaka, Y. Komatsu
Journal: Annals of Oncology (2022)
1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain
Authors: M.R. Garcia Campelo, M. Domine Gomez, J. De Castro Carpeno, A.L. Moreno Vega, S. Ponce Aix, E. Arriola, E. Carcereny Costa, M. Majem Tarruella, G. Huidobro Vence, E. Esteban Gonzalez, J. Fuentes Pradera, A.L.O. Ortega Granados, M. Guillot Morales, B. Massuti Sureda, L. Vila Martinez, A. Blasco Cordellat, C.A. Fajardo, L. Crama, N. Lerones Laborda, M. Cobo Dols
Journal: Annals of Oncology (2022)
272TiP HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC)
Authors: T. Pascual, D.G. Stover, A. Thuerigen, C.M. Perou, E.M. Ciruelos, A. Casas Fernandez Tejerina, P. Spears, E. Roux, H. Hu, Y-S. Lu, S.M. Tolaney, A. Partridge, G. Villacampa Javierre, J.M. Ferrero Cafiero, L. Carey, A. Prat
Journal: Annals of Oncology (2022)
1671P PRECISEKIDS: A nation-wide project for the comprehensive genomic profiling of paediatric solid tumours in Portugal
Authors: J. Lima, J. Pinheiro, H. Barroca, S. Nunes, A. Fernandes, A. Carvalho, M. Jeronimo, I. Luz, C. Mendes, S. Nunes, P. Soares, J.C.L. Machado, M. Gil-da-Costa, M. Bom-Sucesso
Journal: Annals of Oncology (2022)
1656P Durable efficacy of selpercatinib in patients (pts) with medullary thyroid cancer (MTC): Update of the LIBRETTO-001 trial
Authors: M. Kroiss, E.J. Sherman, L.J. Wirth, M.E. Cabanillas, B. Robinson, V. Subbiah, A.E. Drilon, Y. Godbert, N. Fasnacht, V. Soldatenkova, M.S. Xia, C-W. Duann, J. Wright, D. Weiler-Bisig, M. Shah
Journal: Annals of Oncology (2022)
1394P Alkaline phosphatase (ALP) decline and pain response as markers for overall survival (OS) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra) in the REASSURE study
Authors: J. O'Sullivan, D. Heinrich, E. Castro Marcos, S. George, D.Y. Song, S. Dizdarevic, S. Baldari, M. Essler, I.J. de Jong, S. Lastoria, P.G. Hammerer, B. Tombal, N.D. James, F. Verholen, J. Meltzer, P. Sandström, O. Sartor
Journal: Annals of Oncology (2022)
1661MO Genomic somatic copy number alterations drive adaptive tumor immune suppression and primary resistance to anti-PD1 + anti-angiogenics in pleural mesothelioma
Authors: F-X Danlos, C. Baldini, M. Texier, A. Varga, S. Mouraud, B. Job, D. Letourneur, L. Cassard, D. Bredel, S. Laghouati, J. Adam, N. Droin, A. Parpaleix, N. Chaput-Gras, A. Rabeau, C. Massard, J-C. Soria, G. Zalcman, D. Planchard, A. Marabelle
Journal: Annals of Oncology (2022)
1768P Clinical outcomes with platinum-based chemotherapy after progression on frontline immunotherapy in metastatic urothelial cancer (mUC)
Authors: B.E. Szabados, C.F. Stockem, D.E. Castellano Gauna, A. Gomez de Liano Lista, M. Rey Cardenas, B. Perez Valderrama, T.B. Powles, M.S. van der Heijden
Journal: Annals of Oncology (2022)
1648P Deep learning identifies oncogenic genetic alterations in BRAF and NTRK in H&amp;E whole slide images from thyroid carcinomas
Authors: M. Williams, V. Pelekanou, J. Hoehne, J.D. Zoete, A. Schmitz, T.A. Bal, T. Banerji, J. Ferrer, V. Bernard-Gauthier, M. Rudolph, M. Theron, M.E. Cabanillas, M. Lenga, E. Di Tomaso
Journal: Annals of Oncology (2022)
1457P A UK multicentre retrospective review of metastatic renal cell carcinoma (mRCC) patients (pts) outcomes with brain metastases (BM) in the modern era
Authors: G. Ratnayake, A. Challapalli, J. McGrane, R. Frazer, S. Gupta, D.S. Parslow, S.J. Kingdon, A. Lydon, A. Sharma, M. Tuthill, T. McCartney, R. Jabbar, N. Charnley, J.M. Malik, D. Abhi, C. Chau, T.R. Geldart, A. Halstead, U. Anuforom, A. Bahl
Journal: Annals of Oncology (2022)
1630P Effectivity and safety of anti-SARS-CoV2 vaccination in patients with lung cancer: The VAC-CaP observational study (GECP 21/01)
Authors: E. Nadal, M.T. Moran Bueno, D. Rodriguez Abreu, Z. Vidales Sepulveda, M.A. Sala Gonzalez, M. Antonanzas Basa, J.J. Garcia Gonzalez, P. Diz Tain, M. Martinez Kareaga, G. Lopez Vivanco, J. Baena Espinar, B. Campos Balea, D. Cumplido Buron, S. Cerezo Gonzalez, A. Diaz, M. Guirado, X. Mielgo Rubio, O.J. Juan Vidal, M. Saigi Morgui, M. Provencio Pulla
Journal: Annals of Oncology (2022)
1646MO Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma
Authors: C. Dierks, J. Ruf, J. Seufert, M. Kreissl, C. Klein, C. Spitzweg, M. Kroiss, O. Thomusch, K. Lorenz, A. Zielke, C. Miething
Journal: Annals of Oncology (2022)
1379P A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC)
Authors: R. Aggarwal, L. Trihy, E. Hernandez Romero, S. Luch Sam, M. Rastogi, I. De Kouchkovsky, E.J. Small, F. Feng, D. Kwon, T. Friedlander, H.T. Borno, R. Bose, J. Chou, V.S. Koshkin, A. Desai, S. Feng, A. Angelidakis, M.S. Johnson, L. Fong, T. Hope
Journal: Annals of Oncology (2022)
1758P Characteristics, management and survival outcomes of French patients (pts) with muscle invasive bladder cancer (MIBC) at high risk of recurrence (MIBC-HR): A study based on the COBLAnCE cohort
Authors: A. Fraslin, F.P. Colrat, M. Karimi, J. Bonastre, G. Karine, S. Teitsson, A. Prudent, S. Branchoux, F. Radvanyi, S. Benhamou, Y. Allory, T. Lebret
Journal: Annals of Oncology (2022)
1692P ImmTAC redirect T cells against patient-derived tumour organoids and three-dimensional melanospheres: Effects augmented by type I interferons
Authors: P. Kirk, D. Gascoyne, J. Clubley, C. Britton-Rivet, E. Guc, E. Leach, J. Houghton, J. Newton, S. Stanhope, A. Benlahrech
Journal: Annals of Oncology (2022)
1496P Trabectedin for patients with advanced soft tissue sarcoma: A non-interventional, prospective, multicenter study
Authors: V. Grünwald, D. Pink, G. Egerer, E. Schalk, M. Augustin, C.K. Deinzer, V. Kob, D. Reichert, M. Kebenko, S.F. Brandl, D.A. Hahn, L.H. Lindner, M. Hoiczyk, U. Ringsdorf, L. Hanker, D. Hempel, M.J. Pontes, T. Wismann, P. Ivanyi
Journal: Annals of Oncology (2022)
1469P Efficacy and safety of pembrolizumab/axitinib combination in metastatic renal cell carcinoma (mRCC): A multicentric prospective analysis (ProPAXI study)
Authors: A. Guida, M. Maruzzo, E. Lai, D. Bimbatti, F. Pierantoni, M. Dionese, C. Caserta, C. Mosillo, M.L. Calandrella, S. Macrini, G. Fornarini, E. Zanardi, A. Damassi, F. Calabrò, L. Cerbone, S. Astore, L. Galli, S. Bracarda
Journal: Annals of Oncology (2022)
1644O Donafenib in locally advanced/metastatic, radioactive iodine-refractory, differentiated thyroid cancer: A randomized, double-blind, placebo-controlled, multi-center phase III clinical trial (DIRECTION)
Authors: Y. Lin, H. Yang, F. Shi, A. Yang, X. Han, B. Liu, Z. Li, Q. Ji, L. Tang, Z. Deng, Y. Ding, W. Fu, X. Xie, L. Li, X. He, Z. Lv, L. Wu, L. Liu
Journal: Annals of Oncology (2022)
1726P Investigating adipocytes-tumor cells interaction and its effect on disease progression in lobular breast cancer with spatial transcriptomics
Authors: M. Serra, L. Collet, M. Rediti, F. Lifrange, D. Venet, N. Occelli, D. Vincent, G. Rouas, D. Larsimont, L. Craciun, X. Wang, D. Gacquer, M. Vikkula, F.P. Duhoux, F. Rothé, C. Sotiriou
Journal: Annals of Oncology (2022)
1545P A multicenter prospective observational study of pre-existing autoantibodies in patients with small cell lung cancer treated with ICI
Authors: Y. Sato, S. Fujiwara, A. Hata, Y. Kida, T. Masuda, H. Amimoto, H. Matsumoto, K. Miyoshi, K. Otsuka, K. Tomii
Journal: Annals of Oncology (2022)
1436P Genotoxic effect of bullying in children and adolescents with and without central nervous system cancer
Authors: C.B. Gonzalez-Alcorta, C.H. Burciaga-Flores, F. Alcorta-Nuñez, M.D.R. Velazco-Campos, L. Rojas-Patlán, D.C. Pérez-Ibave, J.F. Gonzalez Guerrero, O. Vidal-Gutiérrez, L.E. Martínez-De Villarreal, A. Alcorta-Garza
Journal: Annals of Oncology (2022)
1483O Results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma
Authors: E. Gordon, W.A. Tellez, D.A. Brigham, C. Valencia, S.P. Chawla, V. Chua-Alcala, A. Moradhkani
Journal: Annals of Oncology (2022)
1676P Active immunization with a multi-peptide B cell vaccine, targeting trastuzumab and pertuzumab binding sites, prevents the formation of HER-2/neu expressing lung metastases
Authors: J. Tobias, M. Drinic, S. Högler, A. Schmid, E. Garner-Spitzer, L. Kenner, M. Kundi, C. Zieleinski, U. Wiedermann
Journal: Annals of Oncology (2022)
1465P Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) in the United States
Authors: D. Geynisman, P. Chan, N. Robert, L. Chen, V. Del Tejo, L.C. Rosenblatt, S. Huo, G. Doshi
Journal: Annals of Oncology (2022)
1748P 4-factor model to predict response and survival benefit with durvalumab (D) in previously treated metastatic urinary tract carcinoma (mUTC)
Authors: G.P. Sonpavde, C.N. Sternberg, J-L. Lee, U. Emeribe, S.M. Oh, A.R. Dantas De Lima, S.J. Hotte
Journal: Annals of Oncology (2022)
1652P Molecular and pathological patterns of treatment failure in patients treated by RET selective inhibitors for metastatic medullary thyroid carcinoma
Authors: J. Hadoux, A. Al Ghuzlan, L. Lamartina, M. Attard, J-Y. Scoazec, D.M. Hartl, M. Aldea, L. Friboulet, A. Italiano, B. Besse, L. Lacroix, E. Baudin
Journal: Annals of Oncology (2022)
1371P Assessment of whether time to docetaxel impacts outcome when given in metastatic hormone-sensitive prostate cancer (MHSPC) setting
Authors: S. George, R. Gosain, K. Yendamuri, J.M. Boher, G. Gravis Mescam, C.J. Sweeney, A. Hutson
Journal: Annals of Oncology (2022)
276TiP ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician’s choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)
Authors: S.M. Tolaney, E. de Azambuja, L.A. Emens, S. Loi, W. Pan, J. Huang, S.W. Sun, C. Lai, P. Schmid
Journal: Annals of Oncology (2022)
1589P Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC)
Authors: I. Gonzalez Caraballo, R. Martín Lozano, R. Jiménez Rodríguez, B. Lobato Delgado, M.A. Cañete Muñoz, M. Benavente, M. Palma, M.T. De Toro Carmena, B.I. Morón, V.C. Tirado Anula, J. Soto Alsar, M. Bringas Beranek, N. Gutierrez Alonso, C. López Jiménez, A. Gutiérrez Ortiz de la Tabla, D.S. Juliao Caamaño, L. Ortega Morán, J.M. Soria Fernandez, M. Martin Jimenez, A.J. Munoz Martin
Journal: Annals of Oncology (2022)
1647MO BRAF mutated anaplastic thyroid carcinoma: Clinical characteristics and outcome under BRAF inhibitors and chemotherapy in real-life practice, a multicentric retrospective study of the French ENDOCAN TUTHYREF network
Authors: C. de la Fouchardiere, A. Jannin, F. Giudici, J. Wassermann, C. Chougnet, D. Drui, Y. Godbert, F. Illouz, S. Bardet, N. Roudaut, M. Batisse Lignier, L. Groussin, M. Klein, S. Zerdoud, L. Lamartina, E. Baudin, F. Borson-Chazot, C. Do Cao, I. Borget, J. Hadoux
Journal: Annals of Oncology (2022)
1649P A proof-of-concept study for detecting ctDNA in rare thyroid cancers
Authors: D.M. Vodopivec Kuri, Y.H. Chen, M.E. Cabanillas, M.I. Hu, N.L. Busaidy, R. Dadu, G. Budde, M. Malhotra, J. Diersing, M.E. Zafereo
Journal: Annals of Oncology (2022)
1472P Biomarkers of the response in metastatic papillary renal cell carcinoma
Authors: M. De Vries-Brilland, N. Rioux-Leclercq, E. Blanc, G. Fromont, G. Gravis Mescam, L. Geoffrois, C.M. Chevreau, M. Gross Goupil, B. Escudier, S. Negrier, L. Albiges
Journal: Annals of Oncology (2022)
1678P The interaction between cancer cells and cancer-associated fibroblasts promotes RAS signalling in squamous cell carcinoma, resulting in an immune-suppressive tumour microenvironment and poorer survival outcomes
Authors: A.J. Rullan, G. Giangreco, Y. Naito, S. Hooper, P. Chakravarty, E. Hirata, K.J. Harrington, E. Sahai
Journal: Annals of Oncology (2022)
1374P Radiographic progression-free survival correlation with time-to-event endpoints: A post hoc analysis of the VISION trial
Authors: M.J. Morris, J.S. de Bono, J. Nagarajah, X.X. Wei, L.T. Nordquist, V.S. Koshkin, A. Vickers, O. Mirante, R. Ghouse, S.T. Tagawa, K. Fizazi
Journal: Annals of Oncology (2022)
1546P Impact of stratification factors on outcomes in limited-stage small cell lung cancer: Analysis of CALGB 30610 (Alliance)/RTOG 0538
Authors: J. Bogart, X. Wang, G. Masters, J. Gao, R. Komaki, L.E. Gaspar, J. Heymach, J.A. Bonner, C. Kuzma, S.N. Waqar, W.J. Petty, T. Stinchcombe, J.D. Bradley, E.E. Vokes
Journal: Annals of Oncology (2022)
1731P Lung cancer predisposition in Li-Fraumeni syndrome: Cohort from Gustave Roussy Institute
Authors: H. Sassi, D. Vasseur, L. Mezquita, D. Planchard, B. Besse, B. Bressac, A. Fievet, O. Cabaret, M.A. Robert De Rancher, S. Cotteret, V. Goldbarg, O. Caron, J-Y. Scoazec, None L. Lacroix, E. Rouleau
Journal: Annals of Oncology (2022)
1536P Synthetic control arm (SCA) analysis of lurbinectedin compared to the standard of care (SoC) among patients with small cell lung cancer (SCLC) previously treated with platinum-based chemotherapy
Authors: D.J. Boyne, H. Shakir, O. Joe-Uzuegbu, D. Dawe, A. Pabani, E. Farah, C. Baratta, W.Y. Cheung, D. Brenner
Journal: Annals of Oncology (2022)
1665P Genomic mutational landscape of solid tumors: Preliminary results from ROME trial
Authors: A. Botticelli, S. Scagnoli, P.F. Conte, C. Cremolini, P.A. Ascierto, F. Cappuzzo, M. Aglietta, F. Mazzuca, E. Capoluongo, G. Blandino, U. Malapelle, M. Nuti, G. D'Amati, B. Cerbelli, G. Pruneri, M. Biffoni, G. Giannini, F. Cognetti, G. Curigliano, P. Marchetti
Journal: Annals of Oncology (2022)
1568P Physical condition in patients with a recent diagnosis of colorectal cancer
Authors: M. Romero-Elias, A. Alvarez-Bustos, D. Garcia Gonzalez, F.F. Franco, R. Aguado, L. Gutierrez Sanz, A. Sanchez Ruiz, H. Cebolla, D. Gonzalez-Cutre, A. Ruiz-Casado
Journal: Annals of Oncology (2022)
1199TiP Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC
Authors: A.E. Lisberg, B. Liu, R. Salehi-Rad, J.M. Lee, L. Tran, K. Krysan, R. Lim, C. Dumitras, Z. Jiang, F. Abtin, R. Suh, S. Genshaft, S. Oh, G.A. Fishbein, C.M. O'Higgins, D. Greenwald, J.W. Goldman, D. Elashoff, E.B. Garon, S. Dubinett
Journal: Annals of Oncology (2022)
1601P Predictors of in-hospital mortality after unplanned admissions among adults with cancer aged 80 years and older
Authors: F. Lazar Neto, C.M.T. Hidalgo Filho, J.W.D. Rocha, V.P. Sobottka, L.T.B. Stangler, G. Benfatti, H. Guedes, M.Z. Claro, R.C. Bonadio, M.D.P.E. Diz, P.M. Hoff
Journal: Annals of Oncology (2022)
1605P Comparison of the prognostic value of comorbidities in older patients with colorectal, breast, prostate or lung cancer: The ELCAPA cohort study
Authors: M-A. Benderra, A. Gonzalez-Serrano, E. Paillaud, C. Martinez-Tapia, T. Cudennec, C. Chouaid, E. Lorisson, A. De la Taille, M. Laurent, E.G.C. Brain, M. Bringuier, J. Gligorov, P. Caillet, F. Canouï-Poitrine
Journal: Annals of Oncology (2022)
1383P Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA)
Authors: R. Reisinger, U. Swami, E.J. Hernandez, N. Sayegh, S. Wesolowski, L. Kiedrowski, P.M. Coelho Barata, R. Nussenzveig, G. Lemmon, M.A. Bilen, E. Heath, L. Nandagopal, H. Babiker, S.K. Pal, M.B. Lilly, B.L. Maughan, M. Yandell, O. Sartor, N. Agarwal
Journal: Annals of Oncology (2022)
616TiP Intra-tumor injection of H101 combined with or without radiotherapy in refractory/recurrent/metastatic gynecological malignancies: A prospective, open-label, multi-center, single-arm study
Authors: Z. Liu, T. Wang, J. Wang, F. Shi, J. Su, Q-Y. Zhang, J. Zhang, F. Wang
Journal: Annals of Oncology (2022)
273TiP ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788
Authors: S.A. Hurvitz, K. Kalinsky, D. Tripathy, G. Sledge, W.J. Gradishar, J. O'Shaughnessy, S. Modi, H. Park, A. McCartney, S. Frentzas, C. Shannon, K. Cuff, R.W. Eek, M. Martin Jimenez, G. Curigliano, G. Jerusalem, C. Huang, M. Press, J. Lu
Journal: Annals of Oncology (2022)
1454P Optimizing ipilimumab in RCC: Results from SAKK 07/17 (CM-980) nivolumab (N) + ipilimumab (Ipi) in mRCC
Authors: F. Stenner-Liewen, R. Cathomas, C.A. Rothermundt, J. Beyer, N. Mach, D. Zihler, A.A. Erdmann, M. Kueng, D. Dietrich, J. Glaus Garzon, A. Lorch, D.R. Berthold, H. Läubli
Journal: Annals of Oncology (2022)
1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC)
Authors: J. Remon Masip, N. Girard, P. Bironzo, S. Novello, J. De Castro Carpeno, L. Bigay-Game, R. Bernabe Caro, L. Greillier, J. Mosquera Martinez, S. Cousin, O.J. Juan Vidal, M. Sampayo-Cordero, B. Besse
Journal: Annals of Oncology (2022)
1488MO Initial results of phase II/III trial of AL102 for treatment of desmoid tumors (DT)
Authors: M.M. Gounder, R.L. Jones, R. Chugh, M. Agulnik, A. Singh, B.A. Van Tine, V. Andelkovic, E. Choy, J. Lewin, R. Ratan, J.B. Kaplan, J. Yovell, G. Gordon, B. Kasper
Journal: Annals of Oncology (2022)
1501P Preliminary analysis of a single-arm, multi-center study of anlotinib combined with toripalimab in first-line treatment of unresectable or metastatic undifferentiated pleomorphic sarcoma
Authors: D. Wu, S.J. Lan, Z. Guo, N.N. Niu, Y.Q. Zhang, J.P. Gui
Journal: Annals of Oncology (2022)
1390P Circulating tumor DNA (ctDNA) and prognosis with PSMA-targeted radionuclide therapy (TRT)
Authors: M. Sun, C. Thomas, F. Orlando, M. Sigouros, J. Osborne, J. Nauseef, A.M. Molina, C. Sternberg, M. Bissassar, S. Singh, F. Khani, D.M. Nanus, K. Ballman, N. Bander, F. Demichelis, H. Beltran, S.T. Tagawa
Journal: Annals of Oncology (2022)
1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial
Authors: M. Meylan, C-M. Sun, R-T. Elaidi, M. Moreira, A. Bougouin, V. Verkarre, M. Bennamoun, C.M. Chevreau, D. Borchiellini, P. Barthelemy, D. Pannier, D. Maillet, M. Gross Goupil, C. Tournigand, E. Braychenko, L. Phan, S. Oudard, W-H. Fridman, C. Sautes-Fridman, Y-A. Vano
Journal: Annals of Oncology (2022)
1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)
Authors: S.M. Gadgeel, J. Al-Mondhiry, M-J. Ahn, S-W. Kim, L. Paz-Ares, H. Prenen, M. Boyer, J.G. Bustamante Alvarez, B. Solomon, S. Huang, M. Minocha, M. Kistler, N. Hashemi Sadraei
Journal: Annals of Oncology (2022)
1734MO Hypoxic bladder cancers have a poorer outcome following hypofractionated vs conventionally fractionated radiotherapy in the BC2001 and BCON randomised trials
Authors: T.A.D. Smith, C.M. West, B. Lane, J. Irlam-Jones, E. More, H. Mistry, P.J. Hoskin, S.A. Hussain, E. Hall, N. Porta, R.A. Huddart, N.D. James, A. Choudhury
Journal: Annals of Oncology (2022)